BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18655527)

  • 1. The actual incidence of congenital adrenal hyperplasia in Brazil may not be as high as inferred--an estimate based on a public neonatal screening program in the state of Goiás.
    Silveira EL; dos Santos EP; Bachega TA; van der Linden Nader I; Gross JL; Elnecave RH
    J Pediatr Endocrinol Metab; 2008 May; 21(5):455-60. PubMed ID: 18655527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants.
    Kopacek C; de Castro SM; Prado MJ; da Silva CM; Beltrão LA; Spritzer PM
    BMC Pediatr; 2017 Jan; 17(1):22. PubMed ID: 28095810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants.
    Nordenström A; Wedell A; Hagenfeldt L; Marcus C; Larsson A
    Pediatrics; 2001 Oct; 108(4):E68. PubMed ID: 11581476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neonatal screening for congenital adrenal hyperplasia in Shanghai areas].
    Gu X; Zhou J; Ye J
    Zhonghua Yu Fang Yi Xue Za Zhi; 2002 Jan; 36(1):16-8. PubMed ID: 11955341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency.
    Kösel S; Burggraf S; Fingerhut R; Dörr HG; Roscher AA; Olgemöller B
    Clin Chem; 2005 Feb; 51(2):298-304. PubMed ID: 15608154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of non-classical congenital adrenal hyperplasia form among children with persistently elevated levels of 17-hydroxyprogesterone after newborn screening.
    Castro PS; Rassi TO; Araujo RF; Pezzuti IL; Rodrigues AS; Bachega TASS; Silva IN
    J Pediatr Endocrinol Metab; 2019 May; 32(5):499-504. PubMed ID: 31028712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels.
    Allen DB; Hoffman GL; Fitzpatrick P; Laessig R; Maby S; Slyper A
    J Pediatr; 1997 Jan; 130(1):128-33. PubMed ID: 9003862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A three-year follow-up of congenital adrenal hyperplasia newborn screening.
    Pezzuti IL; Barra CB; Mantovani RM; Januário JN; Silva IN
    J Pediatr (Rio J); 2014; 90(3):300-7. PubMed ID: 24560529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular profile of newborns with confirmed or suspicious congenital adrenal hyperplasia detected after a public screening program implementation.
    Kopacek C; Prado MJ; da Silva CMD; de Castro SM; Beltrão LA; Vargas PR; Grandi T; Rossetti MLR; Spritzer PM
    J Pediatr (Rio J); 2019; 95(3):282-290. PubMed ID: 29715434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants.
    Güran T; Tezel B; Gürbüz F; Selver Eklioğlu B; Hatipoğlu N; Kara C; Şimşek E; Çizmecioğlu FM; Ozon A; Baş F; Aydın M; Darendeliler F
    J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):13-23. PubMed ID: 30111524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: Outcomes of Extended Pilot Study in 241,083 Infants.
    Güran T; Tezel B; Çakır M; Akıncı A; Orbak Z; Keskin M; Selver Eklioğlu B; Ozon A; Özbek MN; Karagüzel G; Hatipoğlu N; Gürbüz F; Çizmecioğlu FM; Kara C; Şimşek E; Baş F; Aydın M; Darendeliler F
    J Clin Res Pediatr Endocrinol; 2020 Sep; 12(3):287-294. PubMed ID: 32157855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.
    Janzen N; Peter M; Sander S; Steuerwald U; Terhardt M; Holtkamp U; Sander J
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2581-9. PubMed ID: 17456574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of seasonality and manufacturer kit lot changes on 17α-hydroxyprogesterone measurements and referral rates of congenital adrenal hyperplasia in newborns.
    Pearce M; Dauerer E; DiRienzo AG; Caggana M; Tavakoli NP
    Eur J Pediatr; 2017 Jan; 176(1):121-129. PubMed ID: 27900477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal screening for congenital adrenal hyperplasia: transitory elevation of 17-hydroxyprogesterone.
    Huidobro Fernández B; Echeverria Fernández M; Dulin Iñiguez E; Ezquieta Zubicaray B; Roldán Martín MB; Rodríguez Arnao MD; Rodríguez Sánchez A
    J Pediatr Endocrinol Metab; 2011; 24(3-4):155-62. PubMed ID: 21648283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study on newborn screening for congenital adrenal hyperplasia in Beijing.
    Gong LF; Gao X; Yang N; Zhao JQ; Yang HH; Kong YY
    J Pediatr Endocrinol Metab; 2019 Mar; 32(3):253-258. PubMed ID: 30817302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of Taiwanese children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency detected by neonatal screening.
    Liu SY; Lee CT; Tung YC; Chien YH; Hwu WL; Tsai WY
    J Formos Med Assoc; 2018 Feb; 117(2):126-131. PubMed ID: 28392195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year evaluation of a Neonatal Screening Program for congenital adrenal hyperplasia.
    Nascimento ML; Cristiano AN; Campos Td; Ohira M; Cechinel E; Simoni G; Lee Jv; Linhares RM; Silva PC
    Arq Bras Endocrinol Metabol; 2014 Oct; 58(7):765-71. PubMed ID: 25372587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of a precursor-to-product ratio in the evaluation of presumptive positives in newborn screening of congenital adrenal hyperplasia.
    Tieh PY; Yee JK; Hicks RA; Mao CS; Lee WN
    J Perinatol; 2017 Mar; 37(3):283-287. PubMed ID: 27929529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia.
    Cavarzere P; Samara-Boustani D; Flechtner I; Dechaux M; Elie C; Tardy V; Morel Y; Polak M
    Eur J Endocrinol; 2009 Aug; 161(2):285-92. PubMed ID: 19451212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening.
    Hird BE; Tetlow L; Tobi S; Patel L; Clayton PE
    Arch Dis Child; 2014 Feb; 99(2):158-64. PubMed ID: 24225272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.